Samrat Pharmachem Ltd
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number ・Standalone data |
|
||||||||||
| Debtors Turnover Days Days ・Standalone data |
|||||||||||
| Iodine Crude Consumption / Volume MT ・Standalone data |
|||||||||||
| Production of Pharmaceutical Chemicals MT ・Standalone data |
|||||||||||
| Number of Plants Number ・Standalone data |
|||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
30 Mar - Crisil revised Samrat Pharmachem bank facilities rating to BB/Stable/A4+ from BB+/Negative/A4+ on March 30, 2026.
- Closure of Trading Window 25 Mar
-
Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31, 2026
25 Mar - Board meeting on May 30, 2026 to approve audited standalone results for year ended March 31, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Feb - Newspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December, 2025
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today
13 Feb - Q3 (Dec 31, 2025) standalone: PAT loss Rs45.95 lakh; 9M PAT loss Rs127.57 lakh; 9M revenue Rs21,908.84 lakh.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
SPL manufactures pharmaceutical ingredient products. It is a major supplier of Iodine Derivatives to the Indian and Foreign Market
and is also present in Salt, Animal Feed, Textile & Tyre Cord manufacturing segment. Company's facilities approved by leading regulatory agencies such as USFDA, GMP, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA